Back to News
Market Impact: 0.05
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
Source: zacks.com
Healthcare & Biotech
Launched on June 23, 2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed fund designed to provide broad exposure to the healthcare-biotechnology equity segment. The article reports no performance or market-moving developments.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- J&J beats earnings estimates; Middle East conflict weighs on medical-device sales
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Alaunos completes Velaris acquisition, raises $350 million